Remdesivir dry powder for inhalation was previously developed using thin film freezing
(TFF). A single-dose 24-h pharmacokinetic study in hamsters demonstrated that pulmonary …

Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for
emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry …

The respiratory tract, as the first and most afflicted target of many viruses such as SARS-CoV-
2, seems to be the logical choice for delivering antiviral agents against this and other …

Remdesivir is one of the most promising drugs to treat COVID-19 based on the following
facts: remdesivir has a broad-spectrum antiviral mechanism of action; it demonstrated in vitro …

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
etiology of COVID-19 pandemic, resulted in significant harm to the affected countries in …

Intravenous remdesivir (RDV) is US Food and Drug Administration–approved for
hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV …

Remdesivir (RDV) exerts anti-severe acute respiratory coronavirus 2 activity following
metabolic activation in the target tissues. However, the pharmacokinetics and tissue …

Strong infectivity enables coronavirus disease 2019 (COVID-19) to rage throughout the
world. Moreover, the lack of drugs with definite therapeutic effects further aggravates the …

Remdesivir as a drug attracted a very serious consideration of whole Globe in treatment of
the pandemic disease COVID-19. More recently published in-vitro inhibition activity and in …

Abstract The novel coronavirus 2019 (2019-nCoV), formally named severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is a novel human infectious coronavirus. The …